Clinical Effectiveness of Cardiac Resynchronization and Implantable Cardioverter-Defibrillator Therapy in Men and Women With Heart Failure: Findings From IMPROVE HF

Background— Many clinical trials have demonstrated a benefit for cardiac resynchronization (CRT) and implantable cardioverter-defibrillator (ICD) therapies in patients with heart failure and reduced ejection fraction, yet questions have been raised with regard to the benefit of ICDs for women. The purpose of this study was to determine the clinical effectiveness of CRT and ICD therapy as a function of sex in outpatients with heart failure and reduced ejection fraction (⩽35%). Methods and Results— Data from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) were analyzed by device status and sex among guideline-eligible patients for vital status (alive/dead) at 24 months. Multivariate generalized estimating equation analyses were conducted adjusting for baseline patient and practice characteristics. In the ICD/CRT-defibrillator (CRT-D) eligible cohort (n=7748), there were 5485 (71%) men and 2261 (29%) women. In the CRT-pacemaker (CRT-P)/CRT-D eligible cohort (n=1188), there were 824 (69%) men and 364 (31%) women. The clinical benefit associated with ICD/CRT-D therapy was similar in both men and women (men adjusted odds ratio, 0.71; 95% confidence interval, 0.57–0.87; P=0.0012; and women adjusted odds ratio, 0.65; 95% confidence interval, 0.49–0.85; P=0.0019). For CRT-P/CRT-D, the associated benefits showed no significant heterogeneity (men adjusted odds ratio, 0.59; 95% confidence interval, 0.33–1.06; P=0.0793; and women adjusted odds ratio, 0.44; 95% confidence interval, 0.22–0.90; P=0.0243). The device-by-sex interactions were not significant (P=0.4441 for CRT-P/CRT-D and P=0.5966 for ICD/CRT-D). Conclusions— The use of guideline-directed CRT and ICD therapy was associated with substantially reduced 24-month mortality in eligible men and women with heart failure and reduced ejection fraction. Device therapies should be offered to all eligible patients with heart failure, without modification based on sex.

[1]  Bristow.  Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) : Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure , 2004 .

[2]  C. Albert,et al.  Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. , 2008, American heart journal.

[3]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[4]  H. Ghanbari,et al.  Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. , 2009, Archives of internal medicine.

[5]  K. Schulman,et al.  Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. , 2007, JAMA.

[6]  A. Moss,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. , 1996, The New England journal of medicine.

[7]  A. Kadish,et al.  DEFibrillators In Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE). , 2003, Cardiac electrophysiology review.

[8]  D. Mark,et al.  Primary Prevention with Defibrillator Therapy in Women: Results from the Sudden Cardiac Death in Heart Failure Trial , 2008, Journal of cardiovascular electrophysiology.

[9]  Claudia Stöllberger,et al.  Guidelines for device-based therapy of cardiac rhythm abnormalities. , 2009, Heart rhythm.

[10]  John L Sapp,et al.  Cardiac-resynchronization therapy for mild-to-moderate heart failure. , 2010, The New England journal of medicine.

[11]  R. Redberg,et al.  Evaluating sex differences in medical device clinical trials: time for action. , 2012, JAMA.

[12]  D. DeMets,et al.  Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. , 2004, The New England journal of medicine.

[13]  J. Daubert,et al.  The effect of cardiac resynchronization on morbidity and mortality in heart failure. , 2005, The New England journal of medicine.

[14]  Hugh Calkins,et al.  Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. , 2004, The New England journal of medicine.

[15]  S. Solomon,et al.  Cardiac resynchronization therapy is more effective in women than in men: the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) trial. , 2011, Journal of the American College of Cardiology.

[16]  N Engl,et al.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. , 1997, Circulation.

[17]  C. Yancy,et al.  Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. , 2007, JAMA.

[18]  Harlan M Krumholz,et al.  ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemaker , 2008, Circulation.

[19]  William T. Abraham,et al.  Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults , 2013 .

[20]  C. O'connor,et al.  Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. , 2007, American heart journal.

[21]  M. Kosorok,et al.  Cardiac Resynchronization Therapy Reduces the Risk of Hospitalizations in Patients With Advanced Heart Failure: Results From the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) Trial , 2009, Circulation.

[22]  H. Ghanbari,et al.  ICD therapy in women: are men from Mars and women from Venus? , 2010, Heart rhythm.

[23]  Wojciech Zareba,et al.  Cardiac-resynchronization therapy for the prevention of heart-failure events. , 2009, The New England journal of medicine.

[24]  K. Ellenbogen,et al.  Gender Disparity in the Use of Cardiac Resynchronization Therapy in the United States , 2008, Pacing and clinical electrophysiology : PACE.

[25]  J. Oss,et al.  PROPHYLACTIC IMPLANTATION OF A DEFIBRILLATOR IN PATIENTS WITH MYOCARDIAL INFARCTION AND REDUCED EJECTION FRACTION , 2002 .

[26]  J. Kirkpatrick,et al.  Ethnic and racial disparities in cardiac resynchronization therapy. , 2009, Heart rhythm.

[27]  Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. , 2009, American heart journal.